Immuneering annual operating expenses
2020
2021
2022
2023
2024
2025
Immuneering Operating Expenses Growth & History (IMRX)
Immuneering's operating expenses was $59.4M for fiscal 2025.
View full Immuneering company overviewImmuneering annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $59.4M | −$4.7M | −7.33% |
| 2024 | 2024-12-31 | $64.1M | $5.7M | +9.69% |
| 2023 | 2023-12-31 | $58.4M | $6.5M | +12.54% |
| 2022 | 2022-12-31 | $51.9M | $17.1M | +49.09% |
| 2021 | 2021-12-31 | $34.8M | $16.7M | +92.19% |
| 2020 | 2020-12-31 | $18.1M | — | — |
Immuneering quarterly operating expenses
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.0M | $4.2M | +28.75% |
| Q1 2026 | 2026-03-31 | $15.3M | −$149,618 | −0.97% |
| Q4 2025 | 2025-12-31 | $13.8M | −$4.8M | −25.89% |
| Q3 2025 | 2025-09-30 | $15.4M | $106,958 | +0.70% |
| Q2 2025 | 2025-06-30 | $14.8M | −$155,854 | −1.05% |
| Q1 2025 | 2025-03-31 | $15.5M | $158,902 | +1.04% |
| Q4 2024 | 2024-12-31 | $18.6M | $2.3M | +13.84% |
| Q3 2024 | 2024-09-30 | $15.3M | $1.3M | +9.68% |
| Q2 2024 | 2024-06-30 | $14.9M | $1.4M | +10.43% |
| Q1 2024 | 2024-03-31 | $15.3M | $646,176 | +4.40% |
| Q4 2023 | 2023-12-31 | $16.3M | $2.3M | +16.56% |
| Q3 2023 | 2023-09-30 | $13.9M | $719,151 | +5.45% |
| Q2 2023 | 2023-06-30 | $13.5M | $1.8M | +15.50% |
| Q1 2023 | 2023-03-31 | $14.7M | $1.7M | +12.76% |
| Q4 2022 | 2022-12-31 | $14.0M | $2.9M | +26.01% |
| Q3 2022 | 2022-09-30 | $13.2M | $4.4M | +49.97% |
| Q2 2022 | 2022-06-30 | $11.7M | $3.4M | +40.33% |
| Q1 2022 | 2022-03-31 | $13.0M | $6.4M | +98.00% |
| Q4 2021 | 2021-12-31 | $11.1M | — | — |
| Q3 2021 | 2021-09-30 | $8.8M | $4.0M | +84.71% |
| Q2 2021 | 2021-06-30 | $8.3M | $4.5M | +116.40% |
| Q1 2021 | 2021-03-31 | $6.6M | — | — |
| Q3 2020 | 2020-09-30 | $4.8M | — | — |
| Q2 2020 | 2020-06-30 | $3.9M | — | — |
Immuneering operating expenses trends
Over the last five fiscal years, Immuneering's operating expenses increased from $18.1M to $59.4M, a change of $41.3M. The latest reported quarter, Q2 2026, shows $19.0M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immuneering source filings ↗